Literature DB >> 17220297

Tumor necrosis factor receptor 2 signaling induces selective c-IAP1-dependent ASK1 ubiquitination and terminates mitogen-activated protein kinase signaling.

Yongge Zhao1, Dietrich B Conze, John A Hanover, Jonathan D Ashwell.   

Abstract

TRAF2 and ASK1 play essential roles in tumor necrosis factor alpha (TNF-alpha)-induced mitogen-activated protein kinase signaling. Stimulation through TNF receptor 2 (TNFR2) leads to TRAF2 ubiquitination and subsequent proteasomal degradation. Here we show that TNFR2 signaling also leads to selective ASK1 ubiquitination and degradation in proteasomes. c-IAP1 was identified as the ubiquitin protein ligase for ASK1 ubiquitination, and studies with primary B cells from c-IAP1 knock-out animals revealed that c-IAP1 is required for TNFR2-induced TRAF2 and ASK1 degradation. Moreover, in the absence of c-IAP1 TNFR2-mediated p38 and JNK activation was prolonged. Thus, the ubiquitin protein ligase activity of c-IAP1 is responsible for regulating the duration of TNF signaling in primary cells expressing TNFR2.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17220297     DOI: 10.1074/jbc.M609146200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

Review 1.  IAPs: what's in a name?

Authors:  Srinivasa M Srinivasula; Jonathan D Ashwell
Journal:  Mol Cell       Date:  2008-04-25       Impact factor: 17.970

2.  Novel anti-apoptotic mechanism of A20 through targeting ASK1 to suppress TNF-induced JNK activation.

Authors:  M Won; K A Park; H S Byun; K-C Sohn; Y-R Kim; J Jeon; J H Hong; J Park; J H Seok; J M Kim; W-H Yoon; I-S Jang; H M Shen; Z G Liu; G M Hur
Journal:  Cell Death Differ       Date:  2010-05-07       Impact factor: 15.828

Review 3.  Developing Treatments for Chronic Kidney Disease in the 21st Century.

Authors:  Matthew D Breyer; Katalin Susztak
Journal:  Semin Nephrol       Date:  2016-11       Impact factor: 5.299

4.  The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis.

Authors:  Peng Zhang; Pi-Xiao Wang; Ling-Ping Zhao; Xin Zhang; Yan-Xiao Ji; Xiao-Jing Zhang; Chun Fang; Yue-Xin Lu; Xia Yang; Mao-Mao Gao; Yan Zhang; Song Tian; Xue-Yong Zhu; Jun Gong; Xin-Liang Ma; Feng Li; Zhihua Wang; Zan Huang; Zhi-Gang She; Hongliang Li
Journal:  Nat Med       Date:  2017-12-11       Impact factor: 53.440

5.  Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 transcription factor-mediated control of cyclin transcription.

Authors:  Jessy Cartier; Jean Berthelet; Arthur Marivin; Simon Gemble; Valérie Edmond; Stéphanie Plenchette; Brice Lagrange; Arlette Hammann; Alban Dupoux; Laurent Delva; Béatrice Eymin; Eric Solary; Laurence Dubrez
Journal:  J Biol Chem       Date:  2011-06-08       Impact factor: 5.157

6.  An Ubiquitin-like Motif in ASK1 Mediates its Association with and Inhibition of the Proteasome.

Authors:  Jeffrey R Schneider; James P Lodolce; David L Boone
Journal:  J Biochem Pharmacol Res       Date:  2013-09-01

7.  Baculoviral inhibitors of apoptosis repeat containing (BIRC) proteins fine-tune TNF-induced nuclear factor κB and c-Jun N-terminal kinase signalling in mouse pancreatic beta cells.

Authors:  B M Tan; N W Zammit; A O Yam; R Slattery; S N Walters; E Malle; S T Grey
Journal:  Diabetologia       Date:  2012-12-20       Impact factor: 10.122

8.  Mutant p53 disrupts the stress MAPK activation circuit induced by ASK1-dependent stabilization of Daxx.

Authors:  Tetsuya Kitamura; Yayoi Fukuyo; Masahiro Inoue; Nobuko T Horikoshi; Masanobu Shindoh; Buck E Rogers; Anny Usheva; Nobuo Horikoshi
Journal:  Cancer Res       Date:  2009-09-29       Impact factor: 12.701

9.  Non-canonical NF-κB activation and abnormal B cell accumulation in mice expressing ubiquitin protein ligase-inactive c-IAP2.

Authors:  Dietrich B Conze; Yongge Zhao; Jonathan D Ashwell
Journal:  PLoS Biol       Date:  2010-10-26       Impact factor: 8.029

10.  Heat shock protein 90-β over-expression is associated with poor survival in stage I lung adenocarcinoma patients.

Authors:  Yongkai Wu; Bo Huang; Qian Liu; Yongyu Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.